Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients

Acta Radiologica

Volumn 52, Issue 2, 2011, Pages 173-180

  Abdulqadhr, Goran ^a   Molin, Daniel ^a   Åström, Gunnar ^a   Suurküla, Madis ^b   Johansson, Lars ^a   Hagberg, Hans ^a   Ahlström, Håkan ^a  

^a Department of Radiology ^*  (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

FDG PET CT; Lymphoma; Whole body diffusion weighted imaging

Indexed keywords

ANN ARBORS; CLINICAL UTILITY; DIFFUSION WEIGHTED IMAGING; FDG-PET; HODGKIN'S LYMPHOMA; LYMPH NODE; LYMPHOCYTIC LEUKEMIA; LYMPHOMA; NON-HODGKIN'S LYMPHOMA; WHOLE-BODY;

COMPUTERIZED TOMOGRAPHY; DIFFUSION;

ONCOLOGY;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; EVALUATION; FEMALE; HUMAN; IMAGE PROCESSING; LYMPHOMA; MALE; METHODOLOGY; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; WHOLE BODY IMAGING;

ADOLESCENT; ADULT; AGED; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 79958843357     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2010.100246     Document Type: Article

References (32)

1. Lin C, Luciani A, Itti E, et al. Whole body MRI and PET/CT in haematological malignancies. Cancer Imaging 2007;7:S88-S93 (Pubitemid 350120940)
2. Schaefer JF, Schlemmer HPW. Total-body MR-imaging in oncology. Eur Radiol 2006;16:2000-15 (Pubitemid 44193185)
3. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-32. (Pubitemid 38552885)
4. Tsushima Y, Takano A, Taketomi-Takahashi A, et al. Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: Usefulness and necessity of referring to T2-weighted images and creating fusion images. Acad Radiol 2007;14:643-50 (Pubitemid 46898198)
5. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001;12:825-30 (Pubitemid 32655093)
6. Schmidt GP, Kramer H, Reiser MF. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology. Top Magn Reson Imaging 2007;18:193-202 (Pubitemid 47357421)
7. Komori T, Narabayashi I, Matsumura K, et al. 2-[Fluorine-18]-fluoro-2- deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: Initial experience. Ann Nucl Med 2007;21:209-15 (Pubitemid 47387439)
8. Lauenstein TC, Semelka RC. Emerging techniques: whole-body screening and staging with MRI. J Magn Reson Imaging 2006;24:489-98 (Pubitemid 44320550)
9. Kwee TC, Takahara T, Ochiai R, et al. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): Features and potential applications in oncology. Eur Radiol 2008;18:1937-52
10. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: Applications and challenges in oncology. Am J Roentgenol 2007;188:1622-35 (Pubitemid 46866868)
11. Takahara T, Imai Y, Yamashita T, et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): Technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004;22:275-82 (Pubitemid 39264807)
12. Stecco A, Romano G, Negru M, et al. Whole-body diffusion-weighted magnetic resonance imaging in the staging of oncological patients: Comparison with positron emission tomography computed tomography (PET-CT) in a pilot study. Radiol Med 2009;114:1-17
13. Kwee TC, van Ufford HM, Beek FJ, et al. Whole- body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: Comparison to computed tomography. Invest Radiol 2009;44:683-90
14. Lin C, Luciani A, Itti E, et al. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 2010;20:2027-38
15. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005;55:368-76 (Pubitemid 41677378)
16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244
17. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007;110:3507-16 (Pubitemid 350159614)
18. Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643-51 (Pubitemid 46224066)
19. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-6 (Pubitemid 36857861)
20. Cronin CG, Swords R, Truong MT, et al. Clinical utility of PET/CT in lymphoma. Am J Roentgenol 2010;194:91-103
21. Fueger BJ, Yeom K, Czernin J. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma. Mol Imaging Biol 2009;11:269-74
22. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: Relation to histologic subtypes based on the World Health Organization classification. Cancer 2007;110:652-9 (Pubitemid 47106156)
23. Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006;107:175-83 (Pubitemid 43939045)
24. Tall MA, Thompson AK, Vertinsky T, et al. MR imaging of the spinal bone marrow. Magn Reson Imaging Clin N Am 2007;15:175-98 (Pubitemid 46962316)
25. Shields AF, Porter BA, Churchley S, et al. The detection of bone marrow involvement by lymphoma using magnetic resonance imaging. J Clin Oncol 1987;5:225-30 (Pubitemid 17021603)
26. Kwee TC, Kwee RM, Verdonck LF, et al. Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma. Br J Haematol 2008;141:60-8 (Pubitemid 351350610)
27. Linden A, Zankovich R, Theissen P, et al. Malignant lymphoma: Bone marrow imaging versus biopsy. Radiology 1989;173:335-9 (Pubitemid 19264580)
28. Hoane BR, Shields AF, Porter BA, et al. Detection of lymphomatous bone marrow involvement with magnetic resonance imaging. Blood 1991;78:728-38
29. Steiner RM, Mitchell DG, Rao VM, et al. Magnetic resonance imaging of diffuse bone marrow disease. Radiol Clin North Am 1993;31:383-409 (Pubitemid 23088648)
30. CarrR,BarringtonSF,MadanB, et al.Detectionof lymphomainbonemarrow by whole-body positron emission tomography. Blood 1998;91:3340-6 (Pubitemid 28193885)
31. Plathow C, Walz M, Lichy MP, et al. Cost considerations for whole-body MRI and PET/CT as part of oncologic staging. Radiologe 2008;48:384-96 (Pubitemid 351720456)
32. Kwee TC, Takahara T, Ochiai R, et al. Whole-body diffusion-weighted magnetic resonance imaging. Eur J Radiol 2009;70:409-17